| 张家行 曹春来 侯青宏 乐鹏 黄晓泉 肖拥军.阿必鲁肽：一种超长效Ⅱ型糖尿病治疗新药[J].,2016,16(2):353-357 |
| 阿必鲁肽：一种超长效Ⅱ型糖尿病治疗新药 |
| Albiglutide: Super Long-lasting Ⅱ Diabetes Treatment Drug |
| |
| DOI： |
| 中文关键词: GLP-1 阿必鲁肽 临床试验 |
| 英文关键词: GLP-1 Albiglutide Clinical trials |
| 基金项目:财政部蛋白类生物药和疫苗发展专项；贵州省免疫学研究生教育创新基地2013 年重点培育项目（201303001） |
|
| 摘要点击次数: 1271 |
| 全文下载次数: 0 |
| 中文摘要: |
| 阿必鲁肽（Albiglutide）为新型GLP-1 受体激动剂，可通过与胰岛beta细胞表面的GLP-1 受体结合，激活由细胞膜偶联G蛋白调控的胞内信号传导系统，修复及促进胰岛beta细胞功能，增加胰岛素的分泌，从而降低血糖浓度及糖化血红蛋白(HbA1c)水平，是治疗Ⅱ型糖尿病的理想药物。目前开发的各种长效GLP-1 受体激动剂成为近二十年糖尿病药物的研究热点。本文对一种极具市场潜力的新型GLP-1 受体激动剂阿必鲁肽（Albiglutide）的分子结构、作用机制、剂量研究、药代动力学、药效学以及副作用等临床试验研究进展进行综述。 |
| 英文摘要: |
| Albiglutide, a newtype of GLP -1 receptor agonists, combined with GLP-1 receptors on the surface of the islet beta cells,
activate the cell membrane coupling G-protein regulation of intracellular signal transduction system, repair and promote the islet beta cell
function, increase the secretion of insulin, thus reduce blood sugar and glycated hemoglobin (HbA1c) levels. So it is an ideal drug for the
treatment of Ⅱ diabetes. The current development of long-acting GLP-1 agonists have become the focus diabetes drugs in the nearly
twenty years. In this paper, Albiglutide, a kind of new GLP-1 receptor agonists, has extremely market potential. It summarized research
progress on its molecular structure, mechanism of action and clinical trials which include its dose research, pharmacokinetics,
pharmacodynamics and side effects, etc. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
